Asthma and Stepwise Management PowerPoint Presentation Assignment Brief (NRNP 6521 Advanced Pharmacology, Week 3)

Answer-first summary: This Week 3 assignment for NRNP 6521 Advanced Pharmacology asks you to build a 5- to 6-slide PowerPoint presentation for a staff development meeting on the stepwise approach to asthma treatment. Describe long-term control and quick-relief medication options for an asthma patient from your practice, explain the drugs’ likely effect on that patient, and walk through how the stepwise model guides prescribing decisions. Show how stepping therapy up and down helps clinicians and patients gain and hold control of the disease. Ground every claim in current pharmacology references, apply APA 7th edition, and include speaker notes.

Course Context and Assessment Overview

Walden University’s NRNP 6521 Advanced Pharmacology positions this PowerPoint presentation as a Week 3 applied assessment within the Module 2 focus on respiratory and pulmonary pharmacotherapeutics. The task connects prescribing theory to a real patient encounter drawn from your clinical practicum, so the graduate nursing student demonstrates safe, evidence-based decision-making rather than textbook recall. You act as a nurse practitioner presenting to peers at a staff development meeting, which means the tone should stay professional, concise, and clinically defensible. The presentation format tests your ability to translate the National Asthma Education and Prevention Program (NAEPP) and Global Initiative for Asthma (GINA) frameworks into practical bedside guidance.

Task Description

By Day 7 of Week 3, create a 5- to 6-slide PowerPoint presentation suitable for a staff development meeting on different approaches for implementing the stepwise approach for asthma treatment. Select one asthma patient from your current or recent clinical practice and keep that patient at the center of your explanation. Use the slide body for concise points and place the fuller clinical reasoning in the speaker notes.

Requirements

• Describe long-term control and quick-relief treatment options for the asthma patient from your practice, and address the impact these drugs might have on that patient.
• Explain the stepwise approach to asthma treatment and management as it applies to your selected patient.
• Explain how stepwise management helps health care providers and patients gain and maintain control of the disease; be specific.
• Limit the deck to 5–6 content slides, excluding a title slide and reference slide.
• Add detailed speaker notes to each content slide so the presentation can stand alone during the meeting.
• Support your points with at least three scholarly sources published within the last five years, formatted in APA 7th edition on the reference slide.

Submission

• Due: By Day 7 of Week 3.
• Format: Microsoft PowerPoint (.pptx), APA 7th edition citations and references.
• Length: 5–6 content slides plus title and reference slides, with speaker notes.

Grading Rubric / Marking Criteria

Sample Presentation Answer Writing Help

A strong deck opens by anchoring the patient: a 34-year-old woman with moderate persistent asthma who reports daytime symptoms four days weekly and two night awakenings each month. For her, long-term control rests on a daily inhaled corticosteroid such as budesonide, which lowers airway inflammation and reduces exacerbation frequency, while a short-acting beta-2 agonist like albuterol delivers rescue bronchodilation within minutes. Her step assignment sits at Step 3, so pairing a low-dose ICS with a long-acting beta-2 agonist offers a defensible upgrade when symptoms break through. Recent guidance has shifted practice toward ICS-formoterol as both maintenance and reliever therapy, a model the 2020 Focused Updates to the Asthma Management Guidelines endorse for select patients with moderate-to-severe disease (Cloutier et al., 2020). Stepping therapy up when control slips and down after three months of stability keeps this patient on the lowest effective dose, which trims corticosteroid side effects and cost. I frame the closing slide around a plain message for staff: the stepwise ladder is a shared decision tool, not a rigid script, and patient adherence data should drive every adjustment. That single reframing, backed by validated Asthma Control Test scores, tends to shift a meeting from drug lists toward measurable outcomes.

Evidence Behind Reliever-Maintenance Therapy

The move away from short-acting beta-2 agonist monotherapy carries real safety weight. GINA’s 2023 strategy report warns that SABA-only treatment is linked to higher exacerbation and mortality risk, which is why anti-inflammatory reliever therapy now sits at the base of adult recommendations (Global Initiative for Asthma, 2023). Kaplan et al. (2020) reinforce this with Canadian primary-care data showing that overreliance on rescue inhalers signals poor control and predicts avoidable emergency visits. For the presenting nurse practitioner, that evidence reframes the “impact of drugs” requirement: the harm of undertreated inflammation often outweighs the convenience of quick relief. A dataset worth citing is the SYGMA trials, which found as-needed budesonide-formoterol reduced severe exacerbations compared with SABA reliever alone. Presenting this comparison lets staff see why guideline authors quietly retired the old SABA-first habit.

Common Pitfalls When Assigning a Step

Where do students most often lose marks on this assignment? They misclassify severity and then justify the wrong step. Severity classification and control assessment are separate judgments; you classify severity before starting therapy, then track control once treatment begins, and the two use different criteria. A second frequent error is treating the stepwise ladder as one-directional, ignoring the step-down that reduces inhaled corticosteroid exposure after a stable stretch. Contrast the NAEPP six-step model, which many U.S. programs still teach, with GINA’s track-based approach that leads with ICS-formoterol; naming both shows examiners you understand competing frameworks rather than one memorized chart (Rosenthal & Burchum, 2021). Students also forget to link medication choice to patient-specific factors like adherence, inhaler technique, comorbidities, and cost, all of which the rubric rewards under clinical rationale. Speaker notes are the place to expand this reasoning, since crowded slides drag down the presentation-quality score.

Why This Matters in Practice

Nurse practitioners write most outpatient asthma prescriptions in primary care, so getting step assignment right directly changes exacerbation rates, oral steroid exposure, and emergency department use. A defensible stepwise decision protects patients from both undertreatment and needless high-dose therapy, and it gives staff a shared language during handoffs and audits. Payers and accreditation bodies increasingly track Asthma Control Test scores and controller-to-reliever ratios, so the reasoning you rehearse in this assignment maps onto real quality metrics you will meet after graduation.

Research, Writing, Citation & Referencing Guide

Lead each slide with the clinical point, then support it in the notes; graders scan for accuracy first and polish second. Keep every claim tied to a source no older than five years, and prefer guideline bodies such as NAEPP, GINA, and peer-reviewed pharmacology journals over general web pages. Use APA 7th edition for in-text citations and the reference slide, and cite once or twice per slide rather than stacking references. Define specialist terms the first time they appear, for example ICS (inhaled corticosteroid) and LABA (long-acting beta-2 agonist), so a mixed staff audience follows along.

Frequently Asked Questions

Which patient should I choose for the NRNP 6521 asthma presentation?

Choose an asthma patient from your own clinical practicum whose severity is clearly documented, ideally moderate persistent, because that level lets you demonstrate several steps, both control and rescue medications, and a realistic step-up decision.

How many slides and sources does the asthma stepwise assignment require?

The deck should run 5–6 content slides plus title and reference slides, and Walden expects at least three current scholarly sources cited in APA 7th edition, with speaker notes carrying the detailed rationale.

What is the difference between long-term control and quick-relief asthma medications?

Long-term control drugs such as inhaled corticosteroids reduce underlying airway inflammation and are taken daily, while quick-relief drugs such as albuterol open constricted airways within minutes during acute symptoms and are used as needed.

Does GINA or the NAEPP stepwise model apply to this assignment?

Both are acceptable; the NAEPP six-step model is standard in most U.S. programs, but referencing GINA’s track-based, ICS-formoterol-first strategy alongside it signals stronger command of current evidence.

References / Learning Resources (Suggested)

• Cloutier, M. M., Baptist, A. P., Blake, K. V., Brooks, E. G., Bryant-Stephens, T., DiMango, E., … Wu, T. D. (2020). 2020 Focused Updates to the Asthma Management Guidelines: A report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. Journal of Allergy and Clinical Immunology, 146(6), 1217–1270. https://doi.org/10.1016/j.jaci.2020.10.003
• Global Initiative for Asthma. (2023). Global strategy for asthma management and prevention (2023 update). https://ginasthma.org/reports/
• Kaplan, A., Mitchell, P. D., Cave, A. J., Gagnon, R., Foran, V., & Ellis, A. K. (2020). Effective asthma management: Is it time to let the AIR out of SABA? Journal of Clinical Medicine, 9(4), 921. https://doi.org/10.3390/jcm9040921
• Rosenthal, L. D., & Burchum, J. R. (2021). Lehne’s pharmacotherapeutics for advanced practice nurses and physician assistants (2nd ed.). Elsevier.
• Reddel, H. K., Bacharier, L. B., Bateman, E. D., Brightling, C. E., Brusselle, G. G., Buhl, R., … Boulet, L. P. (2022). Global Initiative for Asthma strategy 2021: Executive summary and rationale for key changes. European Respiratory Journal, 59(1), 2102730. https://doi.org/10.1183/13993003.02730-2021